Abbott Laboratories logo

Abbott Laboratories (ABT)

Market Closed
23 Feb, 20:00
NYSE NYSE
$
115. 29
+3.08
+2.74%
$
195.3B Market Cap
36.49 P/E Ratio
0.79% Div Yield
7,014,478 Volume
4.44 Eps
$ 112.21
Previous Close
Day Range
112.05 115.3
Year Range
105.27 141.23
Want to track ABT and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
ABT earnings report is expected in 49 days (14 Apr 2026)
Abbott Gains From Lingo CGM's Expansion on Android Platform

Abbott Gains From Lingo CGM's Expansion on Android Platform

ABT expands its Lingo biowearable to Android, broadening access to real-time glucose tracking and pushing continuous monitoring into mainstream wellness.

Zacks | 2 months ago
Start the New Year Off With Passive Income: 3 Dividend Kings to Buy Now

Start the New Year Off With Passive Income: 3 Dividend Kings to Buy Now

Dividend stocks may boost your portfolio during any market environment. These particular companies have shown their commitment to dividend payments and growth over time.

Fool | 2 months ago
Here's Why Abbott (ABT) Fell More Than Broader Market

Here's Why Abbott (ABT) Fell More Than Broader Market

In the latest trading session, Abbott (ABT) closed at $122.09, marking a -2.39% move from the previous day.

Zacks | 2 months ago
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know

Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know

Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.

Zacks | 2 months ago
Abbott issues US device correction for some glucose monitors over faulty readings risk

Abbott issues US device correction for some glucose monitors over faulty readings risk

Abbott Laboratories said on Monday it has begun a correction in the United States for certain FreeStyle Libre 3 and FreeStyle Libre 3 Plus glucose monitoring sensors after internal testing showed some units may report falsely low glucose readings.

Reuters | 3 months ago
Why Abbott is paying $21 billion for Exact Sciences and its Cologuard cancer test

Why Abbott is paying $21 billion for Exact Sciences and its Cologuard cancer test

Abbott is getting into the cancer-testing game with its $21 billion acquisition of Cologuard test maker Exact Sciences.

Marketwatch | 3 months ago
Abbott to Acquire Exact Sciences for $21 Billion

Abbott to Acquire Exact Sciences for $21 Billion

Abbott agreed to acquire Exact Sciences for $105 a share, representing a total equity value of about $21 billion.

Wsj | 3 months ago
Exact Sciences Stock Soars. Abbott Is Buying It in Deal Valued at $21 Billion.

Exact Sciences Stock Soars. Abbott Is Buying It in Deal Valued at $21 Billion.

Abbott Laboratories agrees to buy the cancer screening company in a cash deal.

Barrons | 3 months ago
Exact Sciences Stock Jumps on Reported Deal Interest From Abbott Laboratories

Exact Sciences Stock Jumps on Reported Deal Interest From Abbott Laboratories

A report said the conglomerate Abbott Laboratories is close to a deal to acquire the company.

Barrons | 3 months ago
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It

Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It

Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.

Zacks | 3 months ago
Why Is Abbott (ABT) Up 1.3% Since Last Earnings Report?

Why Is Abbott (ABT) Up 1.3% Since Last Earnings Report?

Abbott (ABT) reported earnings 30 days ago. What's next for the stock?

Zacks | 3 months ago
Goldman Sachs Says US Stocks Could Lag for 10 Years: 5 Strong Buy Value Dividend Ideas

Goldman Sachs Says US Stocks Could Lag for 10 Years: 5 Strong Buy Value Dividend Ideas

Goldman Sachs has projected that U.S. stocks will deliver lackluster returns over the next decade primarily due to two key factors: extreme market concentration and elevated valuations.

247wallst | 3 months ago
Loading...
Load More